Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 5, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Longer gap between vaccine doses: Effective or not?

Lambda Variant of SARS COVID-19 identified: More contagious & deadly

Reboxetine and Butyl-bromide: Drugs to solve sleep apnea issues

Longer gap between vaccine doses: Effective or not?
  • BiotechToday
  • World

Longer gap between vaccine doses: Effective or not?

BioTech Today July 8, 2021July 7, 2021

Anjali Kumari, IILM College of Engineering and Technology

Longer gap (up to 45 weeks) between the Covid-19 vaccines may increase the immune response. According to a new study from the University of Oxford in the United Kingdom, it has been stated that a gap of up to 45 weeks between the first and second doses of the Oxford-AstraZeneca vaccine will remain highly effective, and it will help in increasing the body’s immune response. The third dose after that will be able to boost the antibody levels even further.

The study has provided reassurance that a person’s immunity will not get compromised and it will generate an elevated immune response as compared to the usually recommended interval (8-12 weeks). More than six months later after taking the second dose, the “booster” jab further strengthens immunity which also works against the existing variants. The side effects after taking the second and third dose are generally reported to be relatively mild or lower than compared to the first dose.

As new variants of COVID-19 are emerging, the shortage of vaccine supplies is raising concern in many countries, particularly about the immune response due to the extension of gaps between the doses. The countries with low and middle incomes, for example, Bangladesh, are facing a resurgence in the Covid-19 cases and their vaccine supplies are also severely limited. The government is also concerned about how sooner or later “booster” doses should be given so that the Covid-19 cases do not get overwhelmed in the coming winter season.

AstraZeneca’s vaccine is one of the most widely distributed vaccines globally, and the WHO (World Health Organization) recommends a longer gap of a minimum of 8 to 12 weeks between its first and second dose. The study which appears as a preprint has yet to undergo peer reviews. It has also been found that the antibodies which are induced after the first jab have managed to remain elevated up to 1 year to some extent. Are the results encouraging? The results of the ongoing research are encouraging enough, and it has been found that a longer gap between the vaccine doses may actually prove to be very much beneficial and it will certainly result in more antibodies’ production against the SARS COV-2 virus. It will also enhance the cellular immune response in the body.

At the press briefing which was organized by the Science Media Center in London, one of the authors involved in the research study, Professor Teresa Lambe, Ph.D., said that a person gets a very strong induction of antibodies with these longer gaps and it’s very motivating for the countries which are facing limited vaccine supplies. Professor Sir Andrew Pollard, Ph.D., F. Med. Sci., her co-author, also explained that this finding is done keeping in terms with the experience from the other vaccines. He also added that at this moment nobody knows how long can someone sit safely with still good levels of protection, but it is certainly longer than a period of three months.

“Booster” jab effectiveness: It has been mentioned in the research that the third dose of the original vaccine taken after more than six months of the second dose induced a stronger boost and immune response against the SARS -COV-2 virus, which also includes the most common variants. The third dose of the vaccine led to a much higher level of antibodies that were capable of neutralizing the COVID-19 variant (alpha, beta, and delta) as compared to what was seen after the second dose. The researchers also emphasized the fact that whether people would require or need a third “booster” jab is still very much in the air. The volunteers who were enrolled in the clinical trial of the AstraZeneca vaccine experienced less ‘reactogenicity’ (milder side effects) after a delayed gap between the second or a third dose as compared to the first dose. Concluding, the research study only included younger volunteers. A study of older adults is still underway and the results are awaited.

Also read: ICMR-JRF: ENTRANCE EXAM SEPTEMBER, 2021

References:

  1. https://www.medicalnewstoday.com/articles/longer-gap-between-covid-19-vaccine-doses-may-increase-immune-response
  2. https://wap.business-standard.com/article-amp/international/astrazeneca-vaccine-immune-response-higher-with-longer-gap-third-dose-121062801047_1.html
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged antibody production AstraZeneca Booster dose booster jab clinical trials COVID-19 immune response immunity Oxford vaccine SARS-CoV-2 third dose vaccination vaccine doses

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Reboxetine and Butyl-bromide: Drugs to solve sleep apnea issues

BioTech Today July 8, 2021

Shreyas bhat , DY Patil School of biotechnology and bioinformatics What is sleep apnea? Sleep apnea is a sleep disorder in which frequent on and off events of breathing take place repeatedly. If you snore loudly and feel tired even after sleeping for more than 8hrs, you might have sleep apnea. The major types of […]

Reboxetine

Related Post

  • BiotechToday
  • World

The human-associated clade of S. suis.

bioxone June 23, 2021June 22, 2021

Hari Krishnan R, SRM Institute of Science and Technology Many of the fatal infectious diseases caused in humans are “zoonotic”, which means they are transmitted from animals to humans via their consumption or being in close contact. Various human pathogens are yet to be identified which would have the potential to initiate another pandemic, probably […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

COVID-19: Vaccine Development Probe

bioxone October 15, 2020October 15, 2020

Thota Kanishka Rao, Amity University Kolkata Emerged in 2019, and spread rapidly, the Coronavirus Disease 2019 (COVID-19) impacted economies worldwide, overwhelming health-care systems, as it infected millions causing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  To respond, a worldwide effort has been initiated to develop vaccines and therapeutic agents.  For COVID-19 vaccine development, the trimeric […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

You could be at greater COVID risk if you have Neanderthal genes

bioxone October 5, 2020October 5, 2020

-Anuska Sen, Team bioXone Neanderthals also called Homo neanderthalensis or Homo sapiens neanderthalensis are an extinct group of early humans, which was existent almost 40,000 years back. These individuals lived in Eurasia until they became extinct and there are pieces of evidence that till date a certain percentage of Europeans and South Asians are genetically linked to these Neanderthals. […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy